JAGUAR HEALTH, INC. Impairment of Long-Lived Assets Held-for-use
JAGUAR HEALTH, INC. (JAGX) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-08-19
- JAGUAR HEALTH, INC. impairment of long-lived assets held-for-use for the quarter ending 2026-06-30 was $0.00.
- JAGUAR HEALTH, INC. impairment of long-lived assets held-for-use for the quarter ending 2026-03-31 was $0.00.
- JAGUAR HEALTH, INC. impairment of long-lived assets held-for-use for the quarter ending 2025-12-31 was $0.00.
- JAGUAR HEALTH, INC. impairment of long-lived assets held-for-use for the quarter ending 2025-09-30 was $0.00.
- JAGUAR HEALTH, INC. impairment of long-lived assets held-for-use for fiscal 2024 was $0.00.
- JAGUAR HEALTH, INC. impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
- JAGUAR HEALTH, INC. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-19 | $0.00 10-Q · filed 2026-08-19 | $0.00 derived: sum of 3 quarters · filed 2026-08-19 | $0.00 derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-20 | $0.00 derived: sum of 2 quarters · filed 2026-08-19 | $0.00 derived: sum of 3 quarters · filed 2026-08-19 | $0.00 derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-19 | $0.00 derived: sum of 2 quarters · filed 2026-08-19 | $0.00 derived: sum of 3 quarters · filed 2026-08-19 | $0.00 10-Q · filed 2026-08-19 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 4 quarters · filed 2026-04-07 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-04-07 | $0.00 derived: sum of 4 quarters · filed 2026-04-07 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-04-07 | $0.00 derived: sum of 3 quarters · filed 2026-04-07 | $0.00 derived: sum of 4 quarters · filed 2026-04-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | $0.00 derived: sum of 2 quarters · filed 2026-04-07 | $0.00 derived: sum of 3 quarters · filed 2026-04-07 | $0.00 10-K · filed 2026-04-07 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |